home / stock / regn / regn articles

REGN Articles, Regeneron Pharmaceuticals Inc.

Stock Information
Company Name: Regeneron Pharmaceuticals Inc.
Stock Symbol: REGN
Market: NASDAQ
Website: regeneron.com
Menu
REGN REGN Quote REGN Short REGN News REGN Articles REGN Message Board
Get REGN Alerts

News, Short Squeeze, Breakout and More Instantly...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN | Benzinga

NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Re...
What's Going On With Regeneron Pharmaceuticals Stock On Friday? | Benzinga

On Friday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the European Medicines Agency's Committee for Medicinal Products&nb...

Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024 | Benzinga

TARRYTOWN, N.Y., June 27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second...

First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product | Benzinga

On Wednesday, the FDA approved Verona Pharma plc’s (NASDAQ:VRNA) Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructiv...
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM | Benzinga

Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this ag...

Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs | Benzinga

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) released multiple ascending dose (MAD) data from a Phase 1 study evaluating garetosmab (anti-activin A)...

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More | Benzinga

Biotech stocks are high-risk, high-return opportunities that are under the mercy of several make-or-break catalysts, most of which are binary event...
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments | Benzinga

Gilead Sciences, Inc. (NASDAQ:GILD) witnessed a flurry of Wall Street speculation regarding its potential involvement in the obesity drug market. B...

$100 Invested In This Stock 20 Years Ago Would Be Worth $10,000 Today | Benzinga

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 17.85% on an annualized basis producing an average an...

Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market | Benzinga

RBC Capital Markets analyst Brian Abrahams reiterated an Outperform rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), raising the price fore...
Next 10